[1]
|
A. Calmy, N. Ford, B. Hirschel, S. J. Reynolds, L. Lynen, E. Goemaere, F. G. de la Vega, L. Perrin and W. Rodriguez, “HIV Viral Load Monitoring in Resource-Limited Regions: Optional or Necessary?” Clinical Infectious Diseases, Vol. 44, No. 1, 2007, pp. 128-134.
doi:10.1086/510073
|
[2]
|
WHO, “Antiretroviral Therapy for HIV Infection in Adults and Adolescents, Recommendations for a Public Health Approach 2010 Revision,” 2010.
http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf
|
[3]
|
NACO, “Antiretroviral Therapy Guidelines for HIV In-fected Adults and Adolescents Including Post Exposure Prophylaxis,” Ministry of Health and Family Welfare, 2007.
http://www.nacoonline.org/upload/Policies%20&%20Guidelnes/1.%20Antiretroviral%20Therapy%20Guidelines%
20for%20HIVInfected%20Adults%20and%20Adolescents%20Including%20Post-exposure.pdf
|
[4]
|
Y. Pirzada, S. Khuder and H. Donabedian, “Predicting AIDS-Related Events Using CD4 Percentage or CD4 Absolute Counts,” AIDS Research and Therapy, Vol. 3, 2006, p. 20. doi:10.1186/1742-6405-3-20
|
[5]
|
R. Kannangai, A. J. Kandathil, D. L. Ebenezer, G. Nithyanandam, P. Samuel, O. C. Abraham, T. D. Sudarsanam, S. A. Pulimood and G. Sridharan, “Evidence for Lower CD4+ T Cell and Higher Viral Load in Asymptomatic HIV-1 Infected Individuals of India: Implications for Therapy Initiation,” Indian Journal of Medical Microbiology, Vol. 26, No. 3, 2008, pp. 217-221.
doi:10.4103/0255-0857.42031
|
[6]
|
M. Irwin, “Low CD4+ T Lymphocyte Counts: A Variety of Causes and Their Implications to a Multifactorial Model of AIDS,” Virusmyth Homepage, 2001.
“http://www.virusmyth.com/aids/hiv/milowcd4.htm
|
[7]
|
K. Ray, S. M. Gupta, M. Bala, S. Muralidhar and J. Kumar, “CD4/CD8 Lymphocyte Counts in Healthy, HIV-Positive Individuals & AIDS Patients,” Indian Journal of Medical Research, Vol. 124, 2006, pp. 319-330.
|
[8]
|
V. S. Attili, S. Sundar, V. P. Singh and M. Rai, “Validity of Existing CD4+ Classification in North Indians, in Predicting Immune Status,” Journal of Infection, Vol. 51, No.1, 2005, pp. 41-46. doi:10.1016/j.jinf.2004.08.022
|
[9]
|
A. D. Kimmel, M. C. Weinstein, X. Anglaret, S. J. Goldie, E. Losina, Y. Yazdanpanah, E. Messou, K. L. Cotich, R. P. Walensky and K. A. Freedberg, “Monitoring of Antiretroviral Therapy in Resource-limited Settings: Discussion,” Journal of Acquired Immunodeficiency Syndrome, Vol. 54, No. 3, 2010, pp. 258-268.
doi:10.1097/QAI.0b013e3181d0db97
|
[10]
|
B. Boughton, “WHO-Mandated CD4 Monitoring for HIV Shows Poor Sensitivity, Specificity,” 17th Conference on Retroviruses and Opportunistic Infections (CROI), Abstract 111, San Francisco, 18 February 2010.
http://www.medscape.com/viewarticle/717302
|
[11]
|
E. Mylonakis, M. Paliou and J. D. Rich, “Plasma Viral Load Testing in the Management of HIV Infection,” American Family Physician, Vol. 63, No. 3, 2001, pp. 483-490.
|
[12]
|
M. B. Cauldbeck, C. O’Connor, M. B O’Connor, J. A. Saunders, B. Rao, V. G. Mallesh, N. Kotehalappa, P. Kumar, G. Mamtha, C. McGoldrick, R. B. S. Laing and K. S. Satish, “Adherence to Anti-Retroviral Therapy among HIV Patients in Bangalore, India,” AIDS Research and Therapy, Vol. 6, 2009, p. 7.
doi:10.1186/1742-6405-6-7
|
[13]
|
R. Murri, A. Ammassari, A. De Luca, A. Cingolani, P. Marconi, A. W. Wu and A. Antinori, “Self-Reported Non- adherence with Antiretroviral Drugs Predicts Persistent Condition,” HIV Clinical Trials, Vol. 2, No.4, 2001, pp. 323-329. doi:10.1310/KDM0-RU5W-NVTW-N9MC
|
[14]
|
F. Forna, C. A. Liechty, P. Solberg, F. Asiimwe, W. Were, J. Mermin, P. Behumbiize, T. Tong, J. T. Brooks and P. J. Weidle, “Clinical Toxicity of Highly Active Antiretroviral Therapy in a Home-Based AIDS Care Program in Rural Uganda,” Journal of Acquired Immunodeficiency Syndrome, Vol. 44, No.4, 2007, pp. 456-462.
doi:10.1097/QAI.0b013e318033ffa1
|
[15]
|
R. Nuesch, P. Srasuebkul, J. Ananworanich, K. Ruxrungtham, P. Phanuphak and C. Duncombe, “Monitoring the Toxicity of Antiretroviral Therapy in Resource Limited Settings: A Prospective Clinical Trial Cohort in Thailand,” Journal of Antimicrobial Chemotherapy, Vol. 58, No. 3, 2006, pp. 637-644. doi:10.1093/jac/dkl313
|
[16]
|
C. Adje, R. Cheingsong-Popov, T. Roels, G. Djomand, et al., “High Prevalence of Genotypic Antiretroviral (ART) Drug-Resistant HIV-1 Strains among HIV-1-Infected Patients Receiving ART in Abidjan, Ivory Coast,” Conference on Retroviruses and Opportunistic Infections, San Francisco, 30 January - 2 February 2000.
http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=102243620.html
|
[17]
|
P. Scott, E. Arnold, B. Evans, A. Pozniak, G. Moyle, M. Shahmenesh, D. White, J. Shirley, P. Cane and D. Pillay, “Surveillance of HIV Antiretroviral Drug Resistance in Treated Individuals in England:1998-2000,” Journal of Antimicrobial Chemotherapy, Vol. 54, No. 3, 2003, pp. 469-473.
|
[18]
|
J. W. Mellors, A. Munoz, J. V. Giorgi, J. B. Margolick, C. J. Tassoni, P. Gupta, L. A. Kingsley, J. A. Todd, A. J. S. R. Detels, J. P. Phair and C. R. Rinaldo Jr., “Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection,” Annals of Internal Medicine, Vol. 126, 1997, pp. 946-954.
|
[19]
|
S. Napravnik, C. Poole, J. C. Thomas and J. J. Eron Jr., “Gender Difference in HIV RNA Levels: A Meta-Analysis of Published Studies,” Journal of Acquired Immunodeficiency Syndrome, Vol. 31, No. 1, 2002, pp. 11-19. doi:10.1097/01.QAI.0000026906.47530.AB
|
[20]
|
S. B. Shade, C. Rappoport, D. LeSueur and M. C. Eberly, “Gender Differences in Viral Load: Results from Six Clinical Trials,” International Conference on AIDS, Durban, 9-14 July 2000.
http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=102238735.html
|